Breast Cancer Chemosensitivity (Advances in Experimental Medicine and Biology (608))

In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem Breast Cancer Chemosensitivity moves on to focus on the latest findings of molecular mechanisms of drug resistance. These include in-depth discussions on multidrug resistance by P-glycoprotein and the multidrug resistance protein family, resistance to therapeutic agent-induced apoptosis, cell cycle deregulation, deregulation of DNA repair, loss of tumor suppressor genes, integrin-mediated adhesion, insulin-like growth factors, epidermal growth factor, and ErbB2 in modulating breast cancer response to systemic therapy, especially, certain chemotherapeutic agents. Breast Cancer Chemosensitivity provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment. Overview of resistance to systemic therapy in patients with breast cancer / Ana Maria Gonzalez-Angulo, Flavia Morales-Vasquez and Gabriel N. Hortobagyi Roles of multidrug resistance genes in breast cancer chemoresistance / M. Tien Kuo Therapy-induced apoptosis in primary tumors / David J. McConkey Cell cycle deregulation in breast cancer: insurmountable chemoresistance or achilles' heel? / Laura Lambert and Khandan Keyomarsi p53, BRCA1 and breast cancer chemoresistance / Kimberly A. Scata and Wafik S. El-Deiry Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance / Mary M. Zutter Insulin-like growth factors and breast cancer therapy / Xianke Zeng and Douglas Yee EGF receptor in breast cancer chemoresistance / Robert B. Dickson and T.B. Deb Molecular mechanisms of ErbB2-mediated breast cancer chemoresistance / Ming Tan and Dihua Yu Estrogen receptors in resistance to hormone therapy / Matthew H. Herynk and Suzanne A.W. Fuqua Novel approaches for chemosensitization of breast cancer cells: the E1A story / Yong Liao, Dihua Yu and Mien-Chie Hung. Front Matter....Pages i-xiii Overview of Resistance to Systemic Therapy in Patients with Breast Cancer....Pages 1-22 Roles of Multidrug Resistance Genes in Breast Cancer Chemoresistance....Pages 23-30 Therapy-Induced Apoptosis in Primary Tumors....Pages 31-51 Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles’ Heel?....Pages 52-69 p53, BRCA1 and Breast Cancer Chemoresistance....Pages 70-86 Integrin-Mediated Adhesion: Tipping the Balance between Chemosensitivity and Chemoresistance....Pages 87-100 Insulin-Like Growth Factors and Breast Cancer Therapy....Pages 101-112 EGF Receptor in Breast Cancer Chemoresistance....Pages 113-118 Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance....Pages 119-129 Estrogen Receptors in Resistance to Hormone Therapy....Pages 130-143 Novel Approaches for Chemosensitization of Breast Cancer Cells: The E1A Story....Pages 144-169 Back Matter....Pages 171-175 In Breast Cancer Chemosensitivity, a group of world leading experts review critical aspects of resistance to systemic therapy in breast cancer patients. Beginning with a clinical overview of the problem, the book then focuses on the latest findings of molecular mechanisms of drug resistance. Coverage provides an example of using novel approaches for chemosensitization of breast cancer cells that gives readers an idea about the future direction in breast cancer treatment. It allows those who are interested in breast cancer therapy to get a jump-start on critical issues in breast cancer therapeutic resistance. Reviews critical aspects of resistance to systemic therapy in breast cancer patients. Featuring a clinical overview of the problem, this book focuses on the findings of molecular mechanisms of drug resistance. It discusses multidrug resistance by P-glycoprotein and the multidrug resistance protein family